865759-25-7 | Trelagliptin

334618-23-4    4318-56-3    865759-25-7 

[1]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-WO2008/33851,2008,A2Locationinpatent:Page/Pagecolumn39-40

865759-25-7    76-05-1    928201-45-0 

[1]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-WO2008/33851,2008,A2Locationinpatent:Page/Pagecolumn39-40

865759-25-7    110-15-6    1029877-94-8 

[1]CurrentPatentAssignee:ZHEJIANGWANSHENGPHARMACEUTICAL-CN111349075,2020,ALocationinpatent:Paragraph0063-0069

[2]CurrentPatentAssignee:SHANDONGYONGCHENGPHARMACY-CN112480075,2021,ALocationinpatent:Paragraph0016;0021-0030

[3]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-US2017/81305,2017,A1Locationinpatent:Paragraph0426-0429

[4]Yamada,Masatoshi;Hirano,Sayuri;Tsuruoka,Ryoji;Takasuga,Masahiro;Uno,Kenichi;Yamaguchi,Kotaro;Yamano,Mitsuhisa[OrganicProcessResearchandDevelopment,2021,vol.25,#2,p.327-336]

[5]CurrentPatentAssignee:ZHEJIANGUNIVERSITYOFSCIENCEANDTECHNOLOGY;EASTCHINAPHARMACEUTICALGROUPLIMITEDCOLTD-CN105418581,2016,ALocationinpatent:Paragraph0100;0101

[6]CurrentPatentAssignee:HEFEIUNIVERSITYOFTECHNOLOGY-CN112939937,2021,ALocationinpatent:Paragraph0009;0027;0030;0031;0034;0035;0038;0039

[7]CurrentPatentAssignee:SHENZHENQIANHAIJIUHUAINTERNATIONALSUPPLYCHAIN-CN109331019,2019,ALocationinpatent:Paragraph0042;0054-0059;0078;0090-0095;0114;0126-0131

[8]CurrentPatentAssignee:ZHENGZHOUMINGZEMEDICINETECH-CN105968093,2018,BLocationinpatent:Paragraph0054;0058;0064;0074

[9]CurrentPatentAssignee:SHIJIAZHUANGHUAXINPHARMACEUTICAL-CN112552281,2021,ALocationinpatent:Paragraph0034;0041-0043;0045;0046;0053-0055;0056;0063

[10]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED;CURIAINC-WO2008/67465,2008,A1Locationinpatent:Page/Pagecolumn50-51

[11]CurrentPatentAssignee:SHANGHAIBOCIMEDPHARMACEUTICALCOLTD;SINOBIOPHARMACEUTICALLIMITED-CN105669645,2016,ALocationinpatent:Paragraph0042;0043;0045

[12]CurrentPatentAssignee:SSYGROUPLIMITED-CN105541793,2016,ALocationinpatent:Paragraph0017-0019

[13]CurrentPatentAssignee:HAISCOPHARMACEUTICALGROUPCO.,LTD.-JP2016/509031,2016,ALocationinpatent:Paragraph0158

[14]CurrentPatentAssignee:SICHUANXINSIDUNPHARMACEUTICAL-CN108822080,2018,ALocationinpatent:Paragraph0027;0029-0030;

[15]CurrentPatentAssignee:SHANGHAIFOSUNPHARMACEUTICAL(GROUP)CO.,LTD.-CN109970706,2019,ALocationinpatent:Paragraph0031-0038

[16]Bai,Jie;Leng,Jiewu;Li,Qinglan;Liu,Zihong;Qian,Menglin;Xu,Kailin;Zhao,Suqing;Zhong,Shijuan[CrystEngComm,2020,vol.22,#47,p.8256-8265]

928201-45-0    865759-25-7 

[1]CurrentPatentAssignee:CURIAINC;TAKEDAPHARMACEUTICALCOMPANYLIMITED-WO2008/67465,2008,A1Locationinpatent:Page/Pagecolumn50-51

865759-25-7    75-75-2   

CASUnavailable 

[1]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-US2009/275750,2009,A1Locationinpatent:Page/Pagecolumn31

Title: Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.

Journal: Journal of medicinal chemistry 20110127

Title: Bhumika D Patel, et al. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. Eur J Med Chem. 2014 Mar 3;74:574-605.

Title: Charles E Grimshaw, et al. Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism. PLoS One. 2016 Jun 21;11(6):e0157509.

Title: Shiliang Li, et al. Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes. J Med Chem. 2019 Mar 14;62(5):2348-2361.